(Q50432973)

13 March 2018

title

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. (English)

1 reference

13 March 2018

enzyme replacement therapy

main subject

0 references

1 reference

Mahoko Furujo

1

1 reference

13 March 2018

Toshihide Kubo

series ordinal

2

1 reference

13 March 2018

Motomichi Kosuga

series ordinal

3

1 reference

13 March 2018

Torayuki Okuyama

series ordinal

4

1 reference

13 March 2018

publication date

28 August 2011

1 reference

13 March 2018

Molecular Genetics and Metabolism

published in

1 reference

13 March 2018

volume

104

1 reference

13 March 2018

issue

4

1 reference

13 March 2018

page(s)

597-602

1 reference

13 March 2018

Management guidelines for mucopolysaccharidosis VI.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Mucopolysaccharidosis VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Improvement of skeletal lesions in mice with mucopolysaccharidosis type vii by neonatal adenoviral gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Otorhinolaryngological manifestations of the mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.029

10.1016/J.YMGME.2011.08.029

7 January 2021

Identifiers

DOI

1 reference

13 March 2018

release_exylj3idxvguno2vxeilktgqzq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/exylj3idxvguno2vxeilktgqzq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

13 March 2018